Previous 10 | Next 10 |
2023-08-04 07:32:09 ET Twist Bioscience press release ( NASDAQ: TWST ): Q3 GAAP EPS of -$1.01 beats by $0.13 . Revenue of $63.74M (+13.6% Y/Y) beats by $3.05M . Total orders received for the third quarter of fiscal 2023 were $63.8 million compared to $59.7 mill...
-- Record revenue of $63.7M in 3QFY23; Increase of 14% over $56.1M in Fiscal 2022 -- -- Orders increased 7% in 3QFY23 over fiscal 2022 to $63.8M -- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic D...
2023-08-03 11:45:32 ET Twist Bioscience ( NASDAQ: TWST ) is scheduled to announce Q3 earnings results on Friday, August 4th, before market open. The consensus EPS Estimate is -$1.06 (+1.9% Y/Y) and the consensus Revenue Estimate is $60.69M (+8.2% Y/Y). Over the last 2 ...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2023 third quarter ended June 30, 2023, before the opening of...
2023-07-18 09:50:16 ET Cathie Wood is one of the most successful investors of our time. Her flagship fund, Ark Innovation ETF (NYSEMKT: ARKK) , has already delivered a market-beating 59% return on capital so far this year. At its peak less than two years ago, the fund was up by over...
Cancer Research Horizons is the innovation arm of Cancer Research UK Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Cancer Research Horizons , the innovation en...
-- TB-222-023 Discovered and Optimized Using Twist’s Synthetic DNA Libraries and Antibody Engineering Services -- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, ...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Chet Gandhi as chief information officer. Mr. Gandhi brings a wealth of experience in leading ...
RNA fusions can be used as biomarkers to identify cancer sub-types and monitor for residual disease Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and CeGaT GmbH , ...
2023-05-30 17:31:44 ET Gainers: Extreme Networks ( EXTR ) +6% . Elevation Oncology ( ELEV ) +6% . Annexon ( ANNX ) +4% . Twist Bioscience Corporation ( TWST ) +4% . Omeros Corporation ( OMER ) +4% . Losers: Ambarella ( ...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...